Trastuzumab for a patient with heavily pretreated gastric cancer plus massive ascites and ovarian metastasis

Gastrointestinal Cancer Research

Volumn 5, Issue 3, 2012, Pages 97-99

  Shitara, Kohei ^a   Yatabe, Yasushi ^a   Yokota, Tomoya ^a   Takahari, Daisuke ^a   Shibata, Takashi ^a   Ura, Takashi ^a   Satoh, Yozo ^b   Kodera, Yasuhiro ^c   Muro, Kei ^a  

^a Department of Clinical Oncology ^*  (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PEMETREXED; TRASTUZUMAB;

ABDOMINAL DISTENSION; ADULT; ANOREXIA; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; DUODENOSCOPY; DYSPNEA; FATIGUE; FEMALE; GASTROSCOPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALIGNANT ASCITES; MULTIPLE CYCLE TREATMENT; OVARY METASTASIS; PARACENTESIS; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHYSICAL EXAMINATION; STOMACH BIOPSY; STOMACH CANCER; VOMITING;

EID: 84867890945     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overex-presses HER2. N Engl J Med 344:783-792, 2001
2. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265-4274, 2005
3. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer ver. 2, 2009
4. van Cutsem E, Kang Y, Chung H, et al: Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol27:4265-18, 2009 (suppl; abstr LBA4509)
5. Bang Y, Chung H, Xu J, et al: Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) posi-tivity in the global screening programme of the ToGA trial. J Clin Oncol 27:4265-15s, 2009 (suppl; abstr 4556)
6. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
7. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002